A novel, first in class, potent, orally bioavailable, brain-penetrant, 11βHSD1 inhibitor1
• Differentiated mechanism of action: blocking cortisol production in the brain
• Symptomatic and disease modifying effects in vivo1
• Well-tolerated – dosed >100 patients/subjects: acceptable clinical safety, toxicity and PK/PD profile1
• Effective human brain concentrations demonstrated1
• XanADu – phase II clinical study underway, dosing subjects with mild AD dementia in USA, UK, AU
• Planning ongoing for additional clinical indications
• Composition of matter IP coverage ≥ 2031, patents granted in all major markets
• XanADu Alzheimer's trial fully funded following completion of ~A$5.3 million capital raise in November 2017
• A range of additional studies adequately funded following completion of ~$17 million capital raising in May 2018
Just happy they have such a strong cash position, $17m +
- Forums
- ASX - By Stock
- ACW
- Boston effect....
Boston effect...., page-57
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ACW (ASX) to my watchlist
|
|||||
Last
2.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $70.50M |
Open | High | Low | Value | Volume |
2.6¢ | 2.6¢ | 2.5¢ | $43.80K | 1.689M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
10 | 3097818 | 2.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.6¢ | 475827 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
10 | 3097818 | 0.025 |
17 | 2304914 | 0.024 |
12 | 2708679 | 0.023 |
5 | 1080040 | 0.022 |
8 | 638980 | 0.021 |
Price($) | Vol. | No. |
---|---|---|
0.026 | 475789 | 2 |
0.027 | 2298610 | 9 |
0.028 | 3253040 | 11 |
0.029 | 1745449 | 9 |
0.030 | 1895696 | 7 |
Last trade - 11.02am 20/08/2024 (20 minute delay) ? |
Featured News
ACW (ASX) Chart |